Equities analysts expect BRAINSWAY LTD/S (NASDAQ:BWAY) to post $6.25 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for BRAINSWAY LTD/S’s earnings. The highest sales estimate is $6.30 million and the lowest is $6.20 million. The business is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that BRAINSWAY LTD/S will report full year sales of $23.05 million for the current fiscal year, with estimates ranging from $23.00 million to $23.10 million. For the next fiscal year, analysts anticipate that the company will post sales of $30.30 million, with estimates ranging from $29.50 million to $31.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last posted its quarterly earnings data on Monday, November 25th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $5.93 million during the quarter, compared to the consensus estimate of $5.75 million.
Several research analysts recently weighed in on BWAY shares. Zacks Investment Research cut shares of BRAINSWAY LTD/S from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. Raymond James dropped their price objective on shares of BRAINSWAY LTD/S from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $15.60.
BWAY stock traded up $0.17 during trading on Thursday, hitting $10.75. The company had a trading volume of 2,300 shares, compared to its average volume of 1,700. The firm has a 50-day moving average price of $10.03 and a 200-day moving average price of $9.74. BRAINSWAY LTD/S has a 12 month low of $8.00 and a 12 month high of $12.39.
Institutional investors have recently modified their holdings of the business. Phoenix Holdings Ltd. bought a new stake in shares of BRAINSWAY LTD/S during the 3rd quarter valued at $2,694,000. Victory Capital Management Inc. bought a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter valued at $157,000. Finally, Noked Capital LTD bought a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter valued at $572,000. Institutional investors own 11.24% of the company’s stock.
About BRAINSWAY LTD/S
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Article: Nikkei 225 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.